THIS CLINICAL ANSWER IS NEW Published Online: 7 MAY 2018
This Cochrane Clinical Answer evaluates alemtuzumab versus interferon beta 1a in people with relapsing-remitting multiple sclerosis.
Sorry, it appears that you don't have a current subscription to COCHRANE CLINICAL ANSWERS.
A subscription to THE COCHRANE LIBRARY is required.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.